Ranitidine disposition in patients with renal impairment. 1983

P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks

Ranitidine disposition has been studied in 12 patients with renal impairment following 50 mg given intravenously and 150 mg given by mouth on separate occasions. The clearance of ranitidine from plasma (y) was correlated with creatinine clearance (x): y = 10.47 + 0.289x,r2 = 0.751, but there was no significant correlation of creatinine clearance with distribution volume or bioavailability. The mean (s.e. mean) distribution volume was 1.62 (0.08) 1/kg and the mean bioavailability 0.81 (0.05). These data suggest that in order to obtain similar ranitidine plasma concentrations in anephric patients and patients with normal renal function, the maintenance dose in the anephric patients should be 25-30% of that for patients with normal renal function.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000897 Anti-Ulcer Agents Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. Anti-Ulcer Drugs,Agents, Anti-Ulcer,Anti Ulcer Agents,Anti Ulcer Drugs,Drugs, Anti-Ulcer
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities

Related Publications

P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
January 1989, International journal of clinical pharmacology research,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
April 1994, The Journal of rheumatology,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
November 1983, Clinical pharmacology and therapeutics,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
December 2012, Journal of clinical pharmacology,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
August 1989, Clinical pharmacology and therapeutics,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
June 1982, International journal of clinical pharmacology, therapy, and toxicology,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
January 1997, European journal of clinical pharmacology,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
May 1993, British journal of anaesthesia,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
September 2000, Clinical pharmacology and therapeutics,
P J Meffin, and N Grgurinovich, and P M Brooks, and J O Miners, and M Cochran, and G Stranks
March 1987, International journal of clinical pharmacology, therapy, and toxicology,
Copied contents to your clipboard!